Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

pembrolizumab 34Specimen Handling 18Paclitaxel 16Magnetic Resonance Spectroscopy 15Carboplatin 14Biopsy 14Nivolumab 13Ipilimumab 12Gemcitabine 10Irinotecan 9abemaciclib 8Radiosurgery 8atezolizumab 7Radiation 7Pemetrexed 7Cisplatin 7Capecitabine 7130-nm albumin-bound paclitaxel 7trastuzumab deruxtecan 6olaparib 6durvalumab 6avelumab 6Docetaxel 6palbociclib 5osimertinib 5adagrasib 5Trastuzumab 5Fulvestrant 5Cetuximab 5Albumin-Bound Paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm Metastasis × Imlunestrant × Clear all
NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡